Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

Authors

Institutions

Publication Details

Journal
The Journal of Headache and Pain
Published
2025-02-03
DOI
https://doi.org/10.1186/s10194-025-01956-x
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

Sarah Lipsius, Sheena K. Aurora, Kathleen A. Day, Nada Hindiyeh et al.
The Journal of Headache and Pain
Migraine and Headache Studies
article

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

Sarah Lipsius, Sheena K. Aurora, Kathleen A. Day, Nada Hindiyeh, Holland C. Detke, Hans-Christoph Diener
article en

Abstract

No abstract available for this paper.
The Journal of Headache and PainVol. 26(1)
Eli Lilly (United States) (US), Syneos Health (United States) (US), Impel Neuropharma (United States) (US), University of Duisburg-Essen (DE)
Eli Lilly and Company
Good health and well-being
Openalex Percentile: Top 98%
Migraine and Headache Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab — Sarah Lipsius, Sheena K. Aurora, et al. · The Journal of Headache and Pain (2025) | TGRS Research Map | TGRS